Halozyme Therapeutics (HALO) vs Kymera Therapeutics (KYMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Halozyme Therapeutics (HALO) over the past year, gaining 97.1% versus a gain of 69.6%. Over five years, HALO leads with a +192.4% price change compared with +96.5% for KYMR. Halozyme Therapeutics is the larger company by market cap ($12.53 billion vs $9.25 billion), about 1.4 times the size.
Halozyme Therapeutics converts more of its revenue into profit, with a net margin of 22.7% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | KYMR |
|---|---|---|
| Share price | $110.42 | $112.40 |
| Market cap | $12.53B | $9.25B |
| 1-day change | +0.53% | +2.84% |
| YTD return | +64.07% | +44.45% |
| 1-year return | +69.59% | +97.12% |
| 5-year return | +192.43% | +96.50% |
| P/E ratio (TTM) | 32.29 | — |
| Forward P/E | 10.39 | — |
| EPS (TTM) | $3.42 | $-3.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $39.21M |
| Revenue growth (YoY) | +37.55% | -16.70% |
| Net income (latest FY) | $316.89M | $-311.35M |
| Gross margin | 83.62% | 0.00% |
| Operating margin | 33.58% | -891.07% |
| Net margin | 22.69% | -794.04% |
| 52-week high | $116.85 | $130.05 |
| 52-week low | $61.23 | $55.26 |
| Distance from 52-week high | -5.50% | -13.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -9.84% | +23.95% |
| Average volume | 2.19M | 705.63K |
| Shares outstanding | 113.50M | 82.26M |
| Employees | 423 | 273 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed HALO by 27.5 percentage points over the past year.
- Halozyme Therapeutics is more profitable, keeping 22.7 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Halozyme Therapeutics grew revenue faster in its latest fiscal year (+37.55% vs -16.70%).
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
HALO vs KYMR FAQ
Which is bigger, Halozyme Therapeutics or Kymera Therapeutics?
Halozyme Therapeutics (HALO) is larger, with a market capitalization of $12.53B compared with $9.25B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, HALO or KYMR?
KYMR returned +97.12% over the past 12 months, compared with +69.59% for HALO (price return, excluding dividends). Past performance does not predict future results.
Are Halozyme Therapeutics and Kymera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.